Introduction
A. Öner Eyüboglu (Ankara, Turkey), M. Lipman (London, United Kingdom)
|  |
Update on lung tuberculosis in children
J. Seddon (London, United Kingdom)
|  |
Clinical standards for tuberculosis infection
M. Lipman (London, United Kingdom)
| |
New drugs and regimens in tuberculosis
C. Lange (Borstel, Germany)
| |
Drivers determining active TB screening yield in different European screening programmes: a comparative analysis.
D. Zenner (London, United Kingdom), D. Brals (Amsterdam, Netherlands), C. Erkens (The Hague, Netherlands), A. Matteeli (Brescia, Italy), J. Nederby Öhd (Stockholm, Sweden), D. Menezes (London, United Kingdom), G. De Vries (Bilthoven, Netherlands), M. Muzyamba (London, United Kingdom), J. Van Rest (The Hague, Netherlands), V. Marchese (Brescia, Italy), R. Aldridge (London, United Kingdom), I. Spruijt (The Hague, Netherlands), J. Were (London, United Kingdom), S. Anderson (London, United Kingdom), K. Lönnroth (Stockholm, Sweden), I. Abubakar (London, United Kingdom), F. Cobelens (Amsterdam, Netherlands)
|   |
Using whole genome sequencing to investigate tuberculosis outbreaks in a large UK city: examining the effectiveness of a stone in pond contact tracing approach
D. Braganza Menezes (Birmingham (West Midlands), United Kingdom), T. Marshall (Birmingham (West Midlands), United Kingdom), E. Tranos (Bristol, United Kingdom), H. Kaur (Birmingham, United Kingdom), E. Robinson (Birmingham, United Kingdom), G. Smith (Birmingham, United Kingdom), M. Dedicoat (Birmingham, United Kingdom)
| |
High prevalence of COPD despite successful tuberculosis treatment
L. Yeung (Sydney, Australia), Z. Liu (Sydney, Australia), K. Ng (Sydney, Australia), A. Byrne (Sydney, Australia)
| |
Symptom Burden After Completion of Tuberculosis Therapy in REMoxTB
C. Tweed (London, United Kingdom), G. Wills (London, United Kingdom), J. Meghji (Liverpool, United Kingdom)
| |
Spirometry and radiological sequelae in post pulmonary tuberculosis: A systematic review
a. goel (New Delhi, India), A. Ray (New Delhi, India), J. Kirtana (New Delhi, India)
| |
Culture conversion at 2 months among patients with rifampicin-susceptible pulmonary tuberculosis: a prospective cohort study
J. Min (Seoul, Republic of Korea), H. Kim (Seoul, Republic of Korea), J. Kim (Seoul, Republic of Korea), K. Lee (Cheongju, Republic of Korea), S. Kim (Cheongju, Republic of Korea), S. Jung (Daejeon, Republic of Korea)
| |
Long-term mortality of post-tuberculous survivors in Korea: a population-based longitudinal study
H. Choi (Seoul, Republic of Korea), H. Lee (Seoul, Republic of Korea), K. Han (Seoul, Republic of Korea), S. Kim (Seoul, Republic of Korea), S. Park (Seoul, Republic of Korea), H. Kang (Ilsan, Republic of Korea), J. Sohn (Seoul, Republic of Korea), D. Shin (Seoul, Republic of Korea)
| |
What is new in tuberculosis: from prevention to treatment
C. Lange (Borstel, Germany)
| |
Debate -Tuberculosis: Rolling out of new drugs without diagnostic capacities
R. Duarte (Porto, Portugal), C. Lange (Borstel, Germany), D. Cirillo (Milan, Italy), Dr. Richard Menzies (Montreal, Canada), V. Le (Ho Chi Min City, Vietnam), T. Ness (Houston, USA), I. Petermane (Riga, Latvia)
Tuesday, 04 October 2022 |  |
Expert interview: Microbiologists on tuberculosis diagnostics
D. Cirillo (Milan, Italy), A. Vasiliu (Houston, USA), A. Morita (Yogyakarta, Indonesia), R. Duarte (Porto, Portugal), C. Lange (Borstel, Germany)
Wednesday, 04 May 2022 | |
Discussion
| |
Late Breaking Abstract - Initiation of patient enrollment in treatment with BPaL in Ukraine: first intermediate results
N. Lytvynenko (Kyiv, Ukraine), M. Pogrebna (Kyiv, Ukraine), Y. Senko (Kyiv, Ukraine), Y. Gamazin (????, Ukraine), I. Terleeva (????, Ukraine)
| |
The role of increasing TIM3 on T cells in patients with nontuberculous mycobacterial lung disease: from immune cell dysfunction to clinical severity
C. Shu (Taipei, Taiwan), P. Wang (BNew Taipei City, Taiwan), M. Wu (Taipei, Taiwan)
| |
Pulmonary non-tuberculous mycobacterial infection in patients without predisposing condition, morphological and immunological overview of a french cohort
E. Catherinot (Suresnes, France), C. Bron (Suresnes, France), J. Rosain (Paris, France), V. Jeanne-Julien (Paris, France), H. Salvator (Suresnes, France), P. Devilliers (Suresnes, France), E. Balloul (Suresnes, France), G. Bonan (Suresnes, France), D. Valeyre (Bobigny, France), G. Le Bourdelles (Suresnes, France), E. Rivaud (Suresnes, France), C. Tcehrakian (Suresnes, France), C. Picard (Suresnes, France), S. Boisson-Dupuis (New-York, United States of America), E. Cardot (Suresnes, France), E. Farfour (Suresnes, France), P. Cahen (Suresnes, France), J. Casanova (Paris, France), J. Bustamante (Paris, France), L. Couderc (Suresnes, France)
| |
The effectiveness of broncho-alveolar lavage for the pathogen detection in children with pulmonary tuberculosis
A. Russkikh (Moscow , Russian Federation), E. Veselova (Moscow , Russian Federation), O. Lovacheva (Moscow , Russian Federation), N. Klevno (Moscow , Russian Federation), A. Panova (Moscow , Russian Federation), A. Gracheva (Moscow , Russian Federation), A. Samoilova (Moscow , Russian Federation), . Vasilyeva (Moscow , Russian Federation)
| |
Residual DNA of Mtb from the bronchoscope channel as a possible cause of false positive results in the diagnosis of tuberculosis
N. Eremeeva (Ekaterinburg (Sverdlovsk Oblast), Russian Federation), A. Cvirenko (Ekaterinburg (Sverdlovsk Oblast), Russian Federation), T. Umpeleva (Ekaterinburg (Sverdlovsk Oblast), Russian Federation), D. Vakhrusheva (Ekaterinburg (Sverdlovsk Oblast), Russian Federation), L. Lavrenchuk (Ekaterinburg (Sverdlovsk Oblast), Russian Federation), A. Minin (Ekaterinburg (Sverdlovsk Oblast), Russian Federation)
| |
Genetic polymorphism and phenotypic resistance of Mycobacterium tuberculosis to fluoroquinolones of different generations
L. Lavrenchuk (Ekaterinburg, Russian Federation), T. Umpeleva (Ekaterinburg, Russian Federation), N. Eremeeva (Ekaterinburg, Russian Federation), D. Vakhrusheva (Ekaterinburg, Russian Federation)
| |
Role of PET CT scans in Tuberculous Meningitis
T. Balamugesh (Vellore, India), R. Sekar (Vellore, India), D. Shankar (Vellore, India), J. Hephzibah (Vellore, India), D. Christopher (Vellore, India)
| |
Availability of drug susceptibility testing to new/re-purposed anti-tuberculosis drugs: a TBnet study
L. Guglielmetti (Paris, France), C. Leu (Bern, Switzerland), G. Günther (Bern, Switzerland), G. Bothamley (London, United Kingdom), C. Lange (Borstel, Germany), F. Van Leth (Amsterdam, Netherlands)
| |
Identification of isoniazid mono-resistance is delayed despite whole genome sequencing
M. Park (London, United Kingdom), M. Coleman (London, United Kingdom), L. Martin (London, United Kingdom), G. Russell (London, United Kingdom), A. Lalvani (London, United Kingdom), G. Satta (London, United Kingdom), O. Kon (London, United Kingdom)
| |
Diversity of genetic profiles of Mycobacterium tuberculosis from Ural region of Russia
T. Umpeleva (Ekaterinburg, Russian Federation), E. Mazurina (Ekaterinburg, Russian Federation), L. Lavrenchuk (Ekaterinburg, Russian Federation), N. Eremeeva (Ekaterinburg, Russian Federation), D. Vakhrusheva (Ekaterinburg, Russian Federation)
| |
Discussion and Q&A
| |
Future of eHealth in TB management: perspectives of patients and medical staff
O. Akkerman (Groningen, Netherlands)
| |
The Implementation Research for Digital Technologies and TB (IR4DTB) toolkit
C. Merle (Geneva, Switzerland)
| |
Adherence to treatment for tuberculosis in the digital era
H. Stagg (Edinburgh, United Kingdom)
| |
Tuberculosis care during the COVID-19 pandemic
G. Migliori (Varese (VA), Italy)
| |
Patients' perspective
T. Karimov (Dushanbe, Tajikistan), S. Gardaliev (Tajikistan)
| |
Discussion
| |
Late Breaking Abstract - Impact of the SARS-CoV-2 pandemic on incidence and phenotype of tuberculosis in a UK hotspot
J. Kim (Leicester, United Kingdom), R. Patel (Leicester, United Kingdom), D. Bell (Leicester, United Kingdom), M. Pareek (Leicester, United Kingdom), H. Thuraisingam (Leicester, United Kingdom), J. Lee (Leicester, United Kingdom), A. Gilmour-Caunt (Leicester, United Kingdom), L. Yorke (Leicester, United Kingdom), G. Woltmann (Leicester, United Kingdom), R. Verma (Leicester, United Kingdom), P. Haldar (Leicester, United Kingdom)
| |
Tuberculosis in the elderly. Clinical aspects and outcomes.
E. Garay Llorente (Bilbao (Bizkaia), Spain), E. Tabernero Huguet (Bilbao (Bizkaia), Spain), T. Rodrigo Sanz (SEPAR, Spain), L. Altube Urrengoetxea (Bilbao (Bizkaia), Spain), J. Medina Gallardo (Sevilla, Spain), N. Ortiz Laza (Bilbao (Bizkaia), Spain), J. Garros Garay (Bilbao (Bizkaia), Spain), J. Rodriguez Lopez (Aviles, Spain), J. Garcia Garcia (SEPAR, Spain), P. Separ (SEPAR, Spain), E. Garay Llorente (Barakaldo, Spain)
| |
Impact of pulmonary tuberculosis on COPD outcomes
N. Faria (Porto, Portugal), M. Costa (Porto, Portugal), J. Gomes (Porto, Portugal), M. Sucena (Porto, Portugal)
| |
Barriers and enablers to implementing TB control strategies in EU and EEA countries: a systematic review
O. Conroy (London, United Kingdom), F. Wurie (London, United Kingdom), S. Collin (London, United Kingdom), M. Edmunds (London, United Kingdom), G. De Vries (The Hague, Netherlands), K. Lönnroth (Stockholm, Sweden), I. Abubakar (London, United Kingdom), S. Anderson (London, United Kingdom), D. Zenner (London, United Kingdom)
| |
Use of inhaled GM-CSF in treatment-refractory NTM infection. An open-label, exploratory clinical trial.
R. Thomson (Brisbane, Australia), G. Waterer (Perth, Australia), M. Loebinger (London, United Kingdom), C. Ganslandt (Hørsholm, Denmark)
| |
Treatment failure of nontuberculosis pulmonary disease after adjunctive surgical resection
N. Kang (Seoul, Republic of Korea), B. Jhun (Seoul, Republic of Korea)
| |
Metformin as an adjunct in treatment of Pulmonary Tuberculosis in Non-Diabetic patients.
S. Pothal (Sambalpur (Odisha), India), I. Samantaray (Sambalpur (Odisha), India), S. Biswal (Sambalpur (Odisha), India)
| |
Outcomes of modified all-oral 9-month treatment regimen for rifampicin-resistant tuberculosis in Belarus
N. Yatskevich (Minsk, Belarus), E. Gurbanova (Tartu, Estonia), H. Hurevich (Minsk, Belarus), M. Dara (Copenhagen, Denmark), A. Yedilbayev (Copenhagen, Denmark), V. Grankov (Copenhagen, Denmark), O. Gozalov (Copenhagen, Denmark), A. Skrahina (Minsk, Belarus)
| |
New definitions of extensively drug resistant tuberculosis: update from the World Health Organization
K. Viney (Geneva, Switzerland), F. Mirzayev (Geneva, Switzerland), N. Linh (Geneva, Switzerland), M. Gegea (Geneva, Switzerland), M. Zignol (Geneva, Switzerland)
| |
The World Health Organization actions on digital health for tuberculosis: perspectives for respiratory medicine
D. Falzon (Genève, Switzerland)
| |
Persistent fever and cytopenia in a patient with pulmonary tuberculosis
S. Hettiarachchi (Kiribathgoda, Sri Lanka)
| |
IP-10 decreases during antituberculous treatment in children with active tuberculosis.
A. Strzelak (Warszawa, Poland), A. Komorowska-Piotrowska (Warszawa, Poland), A. Borowa (Otwock, Poland), M. Krasinska (Otwock, Poland), W. Feleszko (Warszawa, Poland), M. Kulus (Warszawa, Poland)
| |
Role of N-acetylcysteine(NAC) in preventing development of anti tuberculosis therapy(ATT) induced liver injury in pulmonary tuberculosis(PTB) patients, a simple randomized single blind clinical trial
S. Ahmed (Karachi, Pakistan), N. Ahmed Rao (Karachi, Pakistan)
| |
Mortality and associated factors among drug-resistant tuberculosis patients in Portugal, 2000-2016
O. Oliveira (Viseu, Portugal), R. Gaio (Porto, Portugal), T. Rito (Braga, Portugal), M. Correia-Neves (Braga, Portugal), R. Duarte (Porto, Portugal)
| |
Ready steady spit: A community based screening for lung tuberculosis amongst high-risk groups in Aalborg, Denmark
S. Shakar (Aalborg, Denmark), N. Stærke (Aarhus, Denmark), M. Christensen (Aalborg, Denmark), U. Weinreich (Aalborg, Denmark)
| |
Preliminary evaluation of serial interferon-gamma releasing assay testing in NSCLC patients treated with immune checkpoint inhibitors
K. Fujita (Kyoto, Japan), Y. Yamamoto (Kyoto, Japan), O. Kanai (Kyoto, Japan), M. Okamura (Kyoto, Japan), K. Nakatani (Kyoto, Japan), T. Mio (Kyoto, Japan)
| |
Genomic factors associated with katG-S315T in Mycobacterium tuberculosis clinical isolates in Vietnam
N. Hang (Hanoi, Vietnam), M. Hijikata (Tokyo, Japan), S. Maeda (Hokkaido, Japan), A. Miyabayashi (Tokyo, Japan), S. Seto (Tokyo, Japan), N. Diem (Da Nang, Vietnam), N. Yen (Da Nang, Vietnam), P. Thuong (Hanoi, Vietnam), H. Huan (Hanoi, Vietnam), N. Hoang (Hanoi, Vietnam), S. Mitarai (Tokyo, Japan), S. Kato (Tokyo, Japan), N. Keicho (Tokyo, Japan)
| |
The use of the lytic D29 mycobacteriophages for accelerated determination of the drug sensitivity of tuberculosis mycobacteria to first and second-line anti-TB drugs in clinical isolates obtained after initial cultivation
M. Vladimirsky (Moscow, Russian Federation), M. Lapenkova (Moscow, Russian Federation), Y. Alyapkina (Moscow, Russian Federation), I. Vasilyeva (Moscow, Russian Federation), G. Arustamova (Moscow, Russian Federation), P. Philippov (Moscow, Russian Federation)
| |